Zydus Lifesciences Forms 50:50 JV in Sri Lanka

JV Agreement – Signed with Sunshine Healthcare Lanka. Stake – 50% stake in Zydus Sunshine Lifesciences. Investment – Up to USD 5 million. Strategic Focus – Expanding footprint in Sri Lanka and South Asia. 📊 Zydus Lifesciences Financials & Ratios (FY25 Snapshot) Metric Value Implication Revenue ~₹20,500 Cr Driven by pharma & wellness portfolio. Net Profit ~₹2,100 Cr Strong profitability. Debt-to-Equity ~0.4 Moderate leverage. P/E Ratio ~28 Reasonable vs pharma peers. ROE ~15% Efficient capital utilization. Dividend Yield ~1.5% Consistent payouts. 📌 Strategic Insights JV strengthens Zydus’ regional presence in Sri Lanka. Supports expansion in pharma manufacturing and distribution. Enhances access to South Asian healthcare markets. ⚡ Growth Drivers Rising demand for affordable medicines in Sri Lanka. Government push for healthcare infrastructure. Zydus’ strong brand portfolio in India and global markets. ⚠️ Risks Regulatory approvals in Sri Lanka. Currency volatility impacting USD investment. Competitive intensity from regional and global pharma players.